Weakened growth rates of leading PPI inhibitors; domestic ones making advances

Although the growth rates of leading proton pump inhibitors(PPI) have been weakened, their domestic drugs seem to make an advance.

According to the UBIST data of the third quarter of 2015 on the 11^th, 9 of the top 15 products had decreases in outpatient prescription.

AstraZeneca’s Nexium recorded KRW 8.4 billion decreased by 42.5% compared with the same quarter of the last year. Takeda Pharma...